NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has entered into a research collaboration with Ameritox to evaluate the use of Agilent's RapidFire platform in medication monitoring.

The RapidFire system is a high-throughput mass spectrometry platform that was developed for drug screening by Biocius, a spinout of BioTrove that Agilent acquired two years ago. The RapidFire 360 system was launched in May 2010 for the high-throughput screening of in vitro ADME assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.